Mihaela Aldea
机构：Harvard University, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Dana-Farber Cancer Institute
发表论文 6 篇
代表论文
- PP01.07: Activity of Bevacizumab Combined With Chemotherapy in Advanced RET-Rearranged Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)
- PP01.48: Therapeutic Strategies and Immunotherapy Rechallenge Sensitivity After Progression Following Chemoradiation and Consolidation Durvalumab in Unresectable Stage III NSCLC: The POST-PACIFIC Study (2026 · Journal of Thoracic Oncology)
- PP01.28: Outcomes to Systemic Standard-of-Care in Patients with MTAP-deleted Advanced NSCLC (2026 · Journal of Thoracic Oncology)
- PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC (2026 · Journal of Thoracic Oncology)
- OA01.04: Tumor Mutational Burden as a Predictor of Immune-Related Adverse Events in Patients With Advanced Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors (2026 · Journal of Thoracic Oncology)
- PP01.01: Genomic Determinants of Acquired Resistance to BRAF/MEK Inhibitors in BRAF V600E-Mutant Non-Small Cell Lung Cancer (2026 · Journal of Thoracic Oncology)